Plain-English translation of NCT07448038 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a medication called can reduce inflammation in the blood vessels of people who have atherosclerosis (hardening of the arteries). Half of the participants will receive , and half will receive a placebo (inactive pill), while everyone continues their regular heart medications. Researchers want to see if this medication can help prevent serious heart events in people at high risk.
Even when people take standard medications for heart disease, inflammation in the blood vessels remains a major problem that can lead to heart attacks and strokes. This trial is exploring whether reducing this inflammation with this medication could offer additional protection beyond current treatments.
You likely qualify if…
You likely don't qualify if…
You would take a pill by mouth twice a day for 12 weeks — either the new medication or a placebo. You'll attend study visits where researchers will check your health, run blood tests, and possibly do imaging scans to see how the medication is working. Throughout the study, you'll continue taking your regular heart medications while researchers monitor whether the new treatment helps reduce inflammation in your blood vessels.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States